

Original Article

Management of arrhythmias in patients with a tetralogy of Fallot

Jamie A. Decker,¹ Jeffrey J. Kim²

¹Division of Pediatric Cardiology, All Children's Heart Institute, Saint Petersburg, Florida; ²Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Houston, Texas, United States of America

Abstract Although arrhythmias are commonly found in patients with all different types of congenital heart disease, perhaps no patient is at higher risk of late development of arrhythmias that may result in sudden death than in the patient following tetralogy of Fallot repair. Despite major improvement in the surgical repair of this disease, a significant percentage of these patients continue to remain at risk for the late development of arrhythmias, and a small percentage will develop life-threatening arrhythmias and sudden death. Which patients remain at highest risk is still not clearly delineated. Diligent arrhythmia surveillance and aggressive treatment strategies are necessary to minimise this risk. This article highlights important strategies to manage arrhythmia development and prevention in this patient population.

Keywords: Tetralogy of fallot; sudden cardiac death; arrhythmias; congenital heart disease; VT

Arrhythmias in tetralogy of Fallot

SINCE THE FIRST SURGICAL REPAIR OF TETRALOGY OF Fallot by Dr Lillihei in 1955,¹ the surgical approach to tetralogy of Fallot has undergone many advances, and although there is still no consensus to the timing and technique for optimal repair these patients are surviving well into adulthood. Unfortunately, there is still significant morbidity and mortality following surgical repair of tetralogy of Fallot, and a large proportion of the morbidity is related to arrhythmias, both atrial and ventricular. These arrhythmias can be the result of re-entrant tachycardias due to diseased myocardium around surgical scars, from myocardial fibrosis due to haemodynamic derangements due to residual cardiac lesions, or from primary myocardial disease. Therefore, arrhythmia surveillance is critical to the management of children and adults after surgical repair of tetralogy of Fallot.

The most significant haemodynamic derangement in these patients is right ventricular volume and pressure overload from pulmonary insufficiency

and/or stenosis. Every patient will have some degree of right ventricular outflow tract dysfunction and these tend to worsen over time. Pulmonary insufficiency results in volume overload of the right ventricle, causing right ventricular chamber dilation. This in turn can contribute to the widening of the QRS duration, a finding that can be a predilection for ventricular arrhythmias and sudden cardiac death.^{2,3} In addition, patients may be predisposed to decreased left ventricular systolic function, ventricular tachycardia, and sudden cardiac death.⁴ The majority of research in this patient population has focused on ventricular arrhythmias that can lead to sudden death; however, these patients also are at risk for developing supraventricular re-entrant arrhythmias, such as atrial flutter and fibrillation, especially in older individuals. This article will review the mechanism of arrhythmias in patients with tetralogy of Fallot and describe arrhythmia management, in the acute and chronic setting.

Peri-operative arrhythmias

In the modern era, it is known that morbidity and mortality are improved when surgical repair

Correspondence to: J. A. Decker, MD, Division of Pediatric Cardiology, All Children's Heart Institute, 601 5th Street South, Saint Petersburg, Florida, United States of America. Tel: +1 727 767 3333; Fax: +1 727 767 8900; E-mail: jamie.decker@allkids.org

of tetralogy of Fallot occurs at a young age.⁵ Some centres advocate for neonatal repair,⁶ whereas other centres may provide palliative procedures in patients with insufficient pulmonary blood flow with a systemic-to-pulmonary arterial shunt and electively repair them at 3–6 months of age in order to minimise the surgical trauma to the right ventricle.⁷ Both approaches have low post-operative mortality and equal long-term outcomes.⁸ Arrhythmia substrates, such as ventricular pre-excitation, are uncommon in this patient population, although a baseline electrocardiogram should be obtained shortly after birth. In addition to confirming the diagnosis, an echocardiogram will evaluate the cardiac function and identify any lesions that may be haemodynamically significant and therefore precipitate arrhythmias, such as valvar insufficiency/stenosis and chamber dilation, although arrhythmias in this age group are uncommon. Continuous cardiorespiratory monitoring with a telemetry system should be routine during the hospitalisation. Tetralogy of Fallot is associated with genetic syndromes, such as DiGeorge, Velo-Cardio-Facial, and Alagille syndrome, which may have other comorbidities that can affect other organ systems and electrolyte regulation and therefore the predisposition for arrhythmias.

The operative period exposes the neonate with congenital heart disease to a vast array of physiological and non-physiological machinations that further compound the proclivity for arrhythmias. Diligent care to maintain a normal electrolyte and pH balance, ensuring no residual haemodynamic lesions that require intervention and maintenance of

sinus rhythm is critical to minimise the risk of peri-operative arrhythmia development. Antiarrhythmic medications may be necessary when arrhythmias persist despite normalisation of the metabolic milieu, although these often improve in the following several months following surgery.

One post-operative arrhythmia following tetralogy of Fallot repair that is challenging to manage is junctional ectopic tachycardia. It occurs following ventricular septal defect repair or when there is traction applied close to the atrioventricular node and it generally leads to haemodynamic compromise. It is the result of irritation to the atrioventricular node and its associated conduction tissue. This irritation causes excitability of the atrioventricular node, resulting in a rapid narrow-complex tachycardia with atrioventricular dissociation – ventricular rate exceeds the atrial rate – as shown in Figure 1. Complex ventricular septal defect repair, especially those involving the perimembranous area, along with prolonged bypass times are at risk for junctional tachycardia.⁹ Patients can have such profound haemodynamic compromise that might even require extreme mechanical support as rescue, such as extracorporeal membrane oxygenation. Junctional ectopic tachycardia generally occurs in the first 24–48 hours after surgery, and aggressive management is important. Weaning inotropes and cooling the patient are helpful. As a general approach, cooling below 35.5°C is avoided. Overdrive atrial pacing is often attempted to restore atrioventricular synchrony, which is successful as long as the junctional rate can be slowed with medications and other measures. Correcting acidosis and electrolytes




Figure 1.

ECG depicting junctional ectopic tachycardia. Junctional ectopic tachycardia with a bundle branch block following surgical repair of tetralogy of Fallot in a 2-year-old boy. The arrows point to the atrial signals demonstrating the slow atrial rate after administration of amiodarone. ECG = electrocardiogram.

are key strategies. Magnesium in particular should be given if tolerated. If these strategies do not work, then intravenous amiodarone should be promptly initiated. In a neonate with already compromised haemodynamics, care must be given when administering intravenous amiodarone. It should be given in doses of 5 mg/kg and run over 20–60 minutes. Pre-medicating infants with a bolus of calcium chloride often prevents the hypotension that can be seen with rapid amiodarone administration. Procainamide is a second agent that can be used to treat junctional tachycardia. It is less potent than amiodarone and therefore not used as commonly, but may be better tolerated.¹⁰ There is increasing evidence that dexmedetomidine may be useful in post-operative junctional ectopic tachycardia.¹¹ Typically, once sinus rhythm is restored and post-surgical inflammation resolves, this arrhythmia subsides and does not require long-term treatment.

Atrioventricular block can also occur following surgery because of mechanical injury to the atrioventricular node, especially during closure of the ventricular septal defect. Atrioventricular demand pacing should be performed using temporary pacing wires and atrioventricular conduction should be monitored daily. If atrioventricular conduction does not return by post-operative day 10, a permanent epicardial pacing system should be placed.¹² Although late-onset atrioventricular node block was once thought to be a major cause of sudden cardiac death in these patients,¹³ this is no longer thought to be true.

Treatment for peri-operative arrhythmias outside of the post-operative state will vary from institution to institution. Most arrhythmias seem to resolve within the first 6 months of surgery. Consideration should be made to wean off medication within 6–12 months of therapy and continue to monitor for arrhythmia recurrence. Immediate post-operative arrhythmias do not always predict recurrence later in life.

Late-onset arrhythmias

Adolescents and adults following repair of tetralogy of Fallot are prone to developing late-onset supraventricular and ventricular arrhythmias. They are relatively uncommon in the first two decades of life.¹⁴ However, as these patients are surviving late into adulthood, the incidence of arrhythmias becomes relatively high, and accounts for significant morbidity and mortality. The most common cause of death in patients after surgical repair of tetralogy of Fallot is sudden death, presumably from ventricular arrhythmias.^{15,16} Fortunately, the incidence of sudden death is low, with an annual incidence of 0.15.¹⁷ Unfortunately, the arrhythmia burden in this

patient population continues to be quite high. In one recent multi-centre study, 30% of adults with repaired tetralogy of Fallot had a sustained arrhythmia.¹⁴ The majority of these were atrial, although ventricular tachycardia was the most common single arrhythmia subtype. Intra-atrial re-entrant tachycardia and atrial fibrillation were the most common atrial arrhythmias, with atrial fibrillation being more common in those >55 years of age.

The surgical approach to the repair of tetralogy of Fallot has been shown to have a significant impact in the development of arrhythmias. Earlier repairs were performed using a transventricular approach. More contemporary approaches involve transatrial/transpulmonary approaches and valve sparing procedures when possible. Procedures to minimise a ventriculotomy seem to have a low arrhythmia burden in medium-term follow-up.^{18,19} Patients who are repaired at a later age or who have a longer cardiopulmonary bypass run may be factors for post-operative mortality, both early and late.²⁰ The use of a transannular patch has been shown to be a risk factor for the development of late ventricular arrhythmias.¹⁵

Nonetheless, early identification of patients at risk of arrhythmias, in particular ventricular arrhythmias and sudden death, remains challenging. There is no single identified risk factor, other than perhaps resuscitated sudden events, which predicts sudden death. Multiple studies have identified certain haemodynamic and electrophysiological properties that warrant further investigation and perhaps implantable cardioverter-defibrillator implantation for primary prevention. These risk factors include surgical correction at an older age,¹⁵ the use of a transannular patch during the primary repair,¹⁵ moderate to severe pulmonary regurgitation,¹⁵ a history of ventricular tachycardia, a QRS duration >180 ms,¹ and left ventricular systolic and/or dysfunction.¹⁵ In addition, patients with at least moderate tricuspid insufficiency¹⁵ and the presence of right ventricular diastolic dysfunction¹³ correlate with the development of atrial arrhythmias. Risk factors for the development of arrhythmias are summarised in Table 1.

The management of these patients, especially as they become adults, should therefore focus around identifying risk factors. These physiological effects are a continuum and progression is inevitable. Although a patient may not meet criteria at one point in time or be considered high risk at one time is not necessarily true in the following years. Careful diligence must be carried out when ascertaining symptomatology and routine diagnostic testing during follow-up visits. Non-invasive imaging is the mainstay for long-term follow-up of these

Table 1. Risk factors for arrhythmia development after tetralogy of Fallot repair.

Risk factor	SCD	VT*	Atrial fib/flutter	References
Age of repair	++		+	Gatzoulis et al ¹⁵
NSVT with symptoms		+		Koyak et al ⁴⁹
NSVT without symptoms		+		Khairy et al ⁴⁶
LVEDP >12 mmHg		++		Khairy et al ⁴⁶
Ventriculotomy/transannular patch	++	++		Gatzoulis et al ¹⁵ and Khairy et al ⁴⁶
QRS >180 ms	+++	+++		Gatzoulis et al ¹⁵ and Gatzoulis et al ³
Rate of change of QRS (mean 3.5 ms/year)	+	+		Gatzoulis et al ¹⁵
Inducible VT/VF with EP study	++	++		Khairy et al ³⁷
Increased RV pressure		+		Khairy et al ⁴⁶ and Garson ³²
>Moderate PR	++	++		Gatzoulis et al ¹⁵
LV systolic dysfunction	+++	+++		Khairy et al ⁴⁶ and Ghai et al ⁴
Previous repair with systemic to PA shunt			+	Gatzoulis et al ¹⁵
>Moderate TR			+	Gatzoulis et al ¹⁵
RV diastolic dysfunction			+	Quattlebaum et al ¹³

EP = electrophysiology; ICD = implantable cardioverter-defibrillator; LV = left ventricular; LVEDP = left ventricular end-diastolic pressure; NSVT = non-sustained VT; PA = pulmonary artery; PR = pulmonary regurgitation; RV = right ventricular; SCD = sudden cardiac death; TR = tricuspid regurgitation; VF = ventricular fibrillation; VT = ventricular tachycardia

*Includes appropriate ICD discharge data, which do not necessarily predict SCD

patients, primarily with echocardiography, although cardiac magnetic resonance can perhaps more accurately measure right ventricular volumes and diastolic and systolic function, which are important variables in the development of ventricular arrhythmias.²¹ In addition, the degree of fibrosis can be readily characterised by cardiac magnetic resonance, a substrate for ventricular arrhythmias.²² Both systolic⁴ and diastolic dysfunction²³ have been found to be associated with arrhythmia development and should be assessed on every study performed in these patients.

As right ventricular dilation progresses, the QRS duration increases as a result of mechano-electrical interactions.^{2,3} In addition to right ventricular dilation, regional wall motion abnormalities are commonly seen, which contributes to the electrical malady of the right ventricle following tetralogy of Fallot repair.²⁴ Ventricular mass and function has also been shown to cause heterogeneous depolarisation/repolarisation, resulting in a QRS prolongation.²⁵ Multiple studies have demonstrated that a QRS duration >180 ms on a surface electrocardiogram has been associated with ventricular arrhythmias and sudden death, which can be considered a surrogate for the overall health of the right ventricle. Owing to the fact that the right ventricle is subject to more haemodynamic derangements and hence progressive hypertrophy, fibrosis, dilation, and dysfunction over time, the QRS can progressively become more prolonged. Several studies have shown that restoring pulmonary valve competency can slow the progression of haemodynamic derangements and the associated prolongation of QRS duration.

More advanced electrocardiographic parameters may prove to be useful in identifying patients at risk for the development of ventricular arrhythmias. Use of signal-averaged electrocardiogram was shown in one recent study to be more predictive of the development of ventricular arrhythmias than absolute QRS duration on a baseline surface electrocardiogram.²⁶ Microvolt T-wave alternans, a measure of repolarisation homogeneity – variation in beat-to-beat T-wave amplitude – and QT/QT dispersion, another marker for identifying ventricular repolarisation abnormalities, are other electrocardiographic modalities that have been studied in patients with tetralogy of Fallot, although they have not been shown to be superior to QRS duration in predicting risk of ventricular arrhythmias as of yet.^{27,28} Unfortunately, these modalities are not readily available in many centres.

In addition to baseline electrocardiograms, ambulatory Holter monitoring can be a useful adjunct to detecting arrhythmias in these patients, especially in asymptomatic patients.²⁹ One recent study demonstrated that up to 40% of patients following repair of tetralogy of Fallot had arrhythmias on Holter monitoring, the majority of which were asymptomatic.³⁰ Therefore, these should be used routinely during follow-up in patients, especially in older patients in whom the arrhythmia risk is higher. Holters have not been shown to be very specific, however, in predicting which patients will go on to have sudden death.³¹

The presence of premature ventricular contractions was identified as a marker for sudden death in a study by Garson in 1979.³² It was noted that premature ventricular contraction were found on




Figure 2.

VT isthmus following tetralogy of Fallot repair. Schematic of the localisation of anatomic boundaries (blue lines) for VT after repair of CHD and the resulting anatomic isthmuses (red lines). CHD = congenital heart disease; RV = right ventricle; RVOT = right ventricular outflow tract; TA = tricuspid annulus; VSD = ventricular septal defect; VT = ventricular tachycardia. Modified from Zeppenfeld³⁹ with permission.

a resting electrocardiogram in 21 out of 217 adolescents and young adults after tetralogy of Fallot repair and seven of those patients died suddenly, whereas no sudden deaths were observed in the remaining 186 patients. These patients had more significant right ventricular systolic dysfunction and/or right ventricular hypertension, and it is likely that the premature ventricular contractions are a marker for worsening haemodynamics. Harrison et al³³ demonstrated that the presence of frequent premature ventricular contractions predicted the development of sustained ventricular tachycardia. The appearance or increase in ectopy should therefore prompt an investigation to search for right ventricular abnormalities that may give one the propensity of ventricular arrhythmias and sudden death.

Exercise stress testing is a common outpatient test used in older children and adults after repaired tetralogy of Fallot. Arrhythmias are commonly seen during exercise testing, and can be as high as 73%.³⁴ Although ventricular tachycardia is seen in older patients³⁵ and in patients with higher right ventricular pressures,³⁶ no studies have been able to demonstrate that exercise-induced arrhythmias predict sudden cardiac death.

Invasive electrophysiology studies are a useful tool to help identify those patients at high risk of sudden death. A multi-centre retrospective review by Khairy et al demonstrated the significance of programmed ventricular stimulation in repaired tetralogy of Fallot. Out of 252 patients, up to 35% had inducible ventricular arrhythmias, and in multivariate analysis inducible sustained ventricular tachycardia was an independent risk factor for the development of clinical ventricular tachycardia or sudden cardiac death.³⁷ In addition to risk

stratification, both atrial and ventricular ablations can be performed using 3-D electroanatomical mapping to accurately define activation patterns and areas of scar with voltage mapping, critical for re-entrant arrhythmias commonly seen in these patients. Using this technology, up to 98% acute success has been demonstrated in post-operative atrial tachycardia ablations, although recurrence is common.³⁸ Successful ablation of ventricular tachyarrhythmias using voltage mapping to identify critical isthmuses for re-entrant arrhythmias can also be achieved.³⁹ Figure 2 demonstrates the four critical ventricular tachycardia isthmuses following surgical repair of tetralogy of Fallot, which are the targets for ablation of these ventricular arrhythmias. These occur between the right ventricular outflow tract patch and tricuspid annulus (isthmus 1), right ventricular scar from a ventriculotomy and the pulmonary valve (isthmus 2), scar from the ventricular septal defect repair to the pulmonary valve (isthmus 3), and the ventricular septal defect scar to the tricuspid annulus (isthmus 4).³⁹

For patients at risk of ventricular arrhythmias and sudden death, the management strategy should focus on reducing the risk. Pulmonary valve replacement has clearly been shown to improve pulmonary regurgitation, reduce right ventricular chamber size, and stabilise the QRS duration. Multiple studies have shown that severe right ventricular dilation ($>170 \text{ ml/m}^2$) does not improve following pulmonary valve replacement and therefore may not prevent sudden death.^{21,40} Several guidelines have been published that help define timing of pulmonary valve replacements.^{41–43} Whether this changes the risk of ventricular arrhythmias and sudden death still remains debatable. Gatzoulis et al¹⁵ showed that there was no




Figure 3.

Electrocardiographic risk factors for SCD. Known risk factors for sudden cardiac death following tetralogy of Fallot repair. (a) A prolonged QRS in a patient with tetralogy of Fallot, pulmonary atresia. A different patient with palpitations had a non-sustained episode of ventricular tachycardia on a Holter monitor (b) and subsequent inducible ventricular tachycardia/fibrillation on an EP study (c) and underwent ICD implantation. EP = electrophysiology; ICD = implantable cardioverter-defibrillator; SCD = sudden cardiac death; TOF = tetralogy of Fallot.

sudden death in patients following pulmonary valve replacement late after surgical repair in a large cohort, concluding that pulmonary valve replacement may prevent sudden death. However, a more recent retrospective, single-institutional, match-controlled study did not demonstrate a decrease in ventricular tachycardia or survival in patients following late pulmonary valve replacement.⁴⁴ Nonetheless, preservation of right ventricular size and function in order to minimise fibrosis as an arrhythmia substrate and improve haemodynamics is imperative in determining the timing of pulmonary valve replacement. Intra-operative cryoablative techniques can be applied at the time of pulmonary valve replacement, which may decrease the future arrhythmia risk even further.⁴⁵

Implantable cardioverter-defibrillators have been shown to be successful in converting potentially life-threatening ventricular arrhythmias into sinus rhythm, potentially preventing sudden death.^{46,47} Selecting those thought to be high enough risk to benefit from implantable cardioverter-defibrillator implantation still remains unclear. Experiences with implantable cardioverter-defibrillator therapy in tetralogy of Fallot are mixed. Many patients will receive an “appropriate” shock for ventricular tachycardia, although it is unclear whether all those shocks would have resulted in sudden death. In fact, tetralogy of Fallot itself is an independent risk factor for appropriate implantable cardioverter-defibrillator therapy in one multi-centre study looking at adults with congenital heart disease.⁴⁸ Unfortunately, these patients also receive a high number of inappropriate shocks, up to 42% in one study,⁴⁹ and high complication rates continue to be a major problem in this patient population. Therefore, careful consideration of risk factors using the tools mentioned above should be used to help guide which patients will benefit most from implantable cardioverter-defibrillators, as outlined in Figure 3.

Conclusion

Although tremendous advances have been made to the surgical and medical management of patients with tetralogy of Fallot, the risk of arrhythmia development and sudden death remains significant. It is clear that pulmonary insufficiency leads to right ventricular dilatation, which results in scarring and electrical changes that predispose these patients to arrhythmias. Optimal timing for pulmonary valve replacement is still controversial. In addition, the ideal management strategy of patients with arrhythmias, in particular ventricular arrhythmias, can be debated. It does not seem that antiarrhythmics are particularly effective in pre-

venting sudden death in themselves. However, not all patients with ventricular arrhythmias will have sudden death, and thus ongoing risk assessment is important. The technology of catheter ablation of arrhythmias, both in the catheterisation laboratory and intra-operatively, have improved and are necessary components to the treatment of arrhythmias. In addition, implantable cardioverter-defibrillator implantation remains the most effective way to prevent sudden death, although which patients require them is not always clear. Future multi-centre studies may help better answer some of these ongoing questions.

References

1. Lillehei CW, Cohen M, Warden HE, et al. Direct vision intracardiac surgical correction of the tetralogy of Fallot, pentalogy of Fallot, and pulmonary atresia defects; reports of first ten cases. *Ann Surg* 1955; 142: 418–442.
2. Abd El Rahman MY, Abdul-Khaliq H, Vogel M, et al. Relation between right ventricular enlargement, QRS duration, and right ventricular function in patients with tetralogy of Fallot and pulmonary regurgitation after surgical repair. *Heart* 2000; 84: 416–420.
3. Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechano-electrical interaction in tetralogy of Fallot: QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. *Circulation* 1995; 92: 231–237.
4. Ghai A, Silversides C, Harris L, Webb GD, Siu SC, Therrien J. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. *J Am Coll Cardiol* 2002; 40: 1675–1680.
5. Van Arsdell GS, Maharaj GS, Tom J, et al. What is the optimal age for repair of tetralogy of Fallot? *Circulation* 2000; 102 (Suppl 3): III123–III129.
6. Hirsch JC, Mosca RS, Bove EL. Complete repair of tetralogy of Fallot in the neonate: results in the modern era. *Ann Surg* 2000; 232: 508–514.
7. Morales DL, Zafar F, Fraser CD. Tetralogy of Fallot: the right ventricular infundibulum sparing (RVIS) strategy. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* 2009; 12: 54–58.
8. Kanter KR, Kogon BE, Kishbom PM, et al. Symptomatic neonatal tetralogy of Fallot: repair or shunt? *Ann Thorac Surg* 2010; 89: 858–863.
9. Hoffman TM, Bush DM, Wernovsky G, et al. Postoperative junctional ectopic tachycardia: incidence, risk factors, and treatment. *Ann Thorac Surg* 2002; 74: 1607–1611.
10. Madapati R, Byrum CJ, Kavey RE, et al. Procainamide for rate control of postsurgical junctional tachycardia. *Pediatr Cardiol* 2000; 21: 123–128.
11. Chrysostomou C, Beerman L, Shiderly D, et al. Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study. *Anesth Analg* 2008; 107: 1514–1522.
12. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force of Practice Guidelines. *J Am Coll Cardiol* 2008; 51: e1–e62.
13. Quattlebaum TG, Varghese J, Neill CA, et al. Sudden death among post-operative patients with tetralogy of Fallot: a follow-up study of 243 patients for an average of twelve years. *Circulation* 1976; 54: 289–293.

14. Khairy P, Aboulhosen J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot. *Circulation* 2010; 122: 868–875.
15. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmias and sudden cardiac death later after repair of tetralogy of Fallot: a multicentre study. *Lancet* 2000; 356: 975–981.
16. Khairy P, Dore A, Talajic M, et al. Arrhythmias in adult congenital heart disease. *Expert Rev Cardiovasc Ther* 2006; 4: 83–95.
17. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. *J Am Coll Cardiol* 1998; 32: 245–251.
18. Dietl CA, Cazzanigna ME, Dubner SJ, Perez-Balino NA, Torres AR, Favaloro RG. Life-threatening arrhythmias and RV dysfunction after surgical repair of tetralogy of Fallot. Comparison between transventricular and transatrial approaches. *Circulation* 1994; 90: II7–II12.
19. Nui MC, Morris SA, Morales DL, et al. Low incidence of arrhythmias in the right ventricular infundibulum sparing approach to tetralogy of Fallot. *Pediatr Cardiol* 2013, Epub.
20. Hamada H, Terai M, Jibiki T, Nakamura T, Gatzoulis MA, Niwa K. Influence of early repair of tetralogy of Fallot without an outflow patch on late arrhythmias and sudden death: a 27-year follow-up study following a uniform surgical approach. *Cardiol Young* 2002; 12: 345–351.
21. Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. *Heart* 2008; 94: 211–216.
22. Babu-Narayan SV, Kilner PJ, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcomes. *Circulation* 2006; 113: 405–413.
23. Aboulhosen JA, Lluri G, Gurvitz MZ, et al. Left and right ventricular diastolic function in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. *Can J Cardiol* 2013; 29: 866–872.
24. Vogel M, Sponring J, Cullen S, et al. Regional wall motion and abnormalities of electrical depolarization and repolarization in patients after surgical repair of tetralogy of Fallot. *Circulation* 2001; 103: 1669–1673.
25. Helbing WA, Roest AW, Niezen RA, et al. ECG predictors of ventricular arrhythmias and biventricular size and wall mass in tetralogy of Fallot with pulmonary regurgitation. *Heart* 2002; 88: 515–520.
26. Russo G, Folino AF, Mazzotti E, et al. Comparison between QRS duration at standard ECG and signal-averaging ECG for arrhythmic risk stratification after surgical repair of tetralogy of Fallot. *J Cardiovasc Electrophys* 2005; 16: 288–292.
27. Chiu SN, Chiu HH, Wang JK, et al. Increased microvolt T-wave alternans in patients with repaired tetralogy of Fallot. *Int J Card* 2012; 159: 220–224.
28. Berul CI, Hill SL, Geggel RL, et al. Electrocardiographic markers of late sudden death risk in postoperative tetralogy of Fallot children. *J Card Electrophys* 1997; 8: 1349–1356.
29. Czonek RJ, Anderson J, Khoury PR, et al. Utility of ambulatory monitoring in patients with congenital heart disease. *Am J Cardiol* 2013; 111: 723–730.
30. Rodriguez FH, Moodie DS, Neeland M, et al. Identifying arrhythmias in adults with congenital heart disease by 24-h ambulatory electrocardiography. *Pediatr Cardiol* 2012; 33: 591–595.
31. Cullen S, Celermajer DS, Franklin RC, et al. Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study. *J Am Coll Cardiol* 1992; 20: 295–300.
32. Garson Jr A, Nihill MR, McNamara DG, et al. Status of the adult and adolescent after repair of tetralogy of Fallot. *Circulation* 1979; 59: 1232–1240.
33. Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. *J Am Coll Cardiol* 1997; 30: 1368–1373.
34. Roos-Hesselink J, Perlroth M, McGhie J, et al. Atrial arrhythmias in adults after repair of tetralogy of Fallot. Correlations with clinical, exercise and echocardiographic findings. *Circulation* 1995; 91: 2214–2219.
35. Wessel H, Paul M. Exercise studies in tetralogy of Fallot: a review. *Ped Cardiol* 1999; 20: 39–47.
36. Garson A, Gillette P, Gutgesell H, et al. Stress-induced ventricular arrhythmia after repair of tetralogy of Fallot. *Am J Cardiol* 1980; 46: 1006–1012.
37. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of Fallot repair: a multicenter study. *Circulation* 2004; 109: 1994–2000.
38. De Groot NM, Lukac P, Schalij MJ, et al. Long-term outcome of ablative therapy of post-operative atrial tachyarrhythmias in patients with tetralogy of Fallot: a European multi-centre study. *Europace* 2012; 14: 522–527.
39. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. *Circulation* 2007; 116: 2241–2252.
40. Therrien J, Provost Y, Mechant N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. *Am J Cardiol* 2005; 95: 779–782.
41. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee on the management of adults with congenital heart disease). *J Am Coll Cardiol* 2008; 52: E143–E263.
42. Silversides CK, Kiess M, Beauchesne L, et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan's syndrome. *Can J Cardiol* 2010; 26: e80–e97.
43. Baumgartner H, Bonhoeffer P, De Groot NM, et al. Task Force on the management of grown-up congenital heart disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC). *Eur Heart J* 2010; 31: 2915–2957.
44. Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. *Circulation* 2009; 119: 445–451.
45. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. *Circulation* 2001; 103: 2489–2494.
46. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. *Circulation* 2008; 117: 363–370.
47. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. *J Am Coll Cardiol* 2008; 29: 1685–1691.
48. Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of implantable cardioverter defibrillators in adults with congenital heart disease: a multi-centre study. *Eur Heart J* 2007; 28: 1854–1861.
49. Koyak Z, de Groot JR, Bouma BJ, et al. Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. *Int J Cardiol* 2012; 167: 1532–1535.